Literature DB >> 24337343

[Pharmacokinetics of systemic, regional and topical drugs for therapy of intraocular inflammation].

M D Becker1, S Lortz, B Flückiger, V Luginbuehl.   

Abstract

A broad spectrum of anti-inflammatory drugs with different mechanisms is available for the treatment of intraocular inflammation. Corticosteroids are the mainstay of therapy. Mechanisms of action are quite well understood for most drugs in particular taken from animal research studies. However, pharmacokinetic evidence for treatment of ocular disease is generally limited for the human eye and especially for ocular inflammation. The bioavailability of a particular drug in an inflamed eye is expected to be faster due to a barrier breakdown. Therefore, intraocular level of effective substances should be lowered more rapidly than in a non-inflamed eye due to improved drainage. This article reviews current knowledge firstly about local, regional and systemic anti-inflammatory therapy of uveitis and finally on immuosuppressive systemic therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24337343     DOI: 10.1007/s00347-013-2933-8

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  23 in total

1.  Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.

Authors:  Joan-En Chang-Lin; James A Burke; Qing Peng; Ton Lin; Werhner C Orilla; Corine R Ghosn; Kai-Ming Zhang; Baruch D Kuppermann; Michael R Robinson; Scott M Whitcup; Devin F Welty
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-28       Impact factor: 4.799

2.  Intraocular concentration of intravenous prednisolone in experimental autoimmune uveoretinitis mice.

Authors:  Noriyasu Hashida; Nobuyuki Ohguro; Yukio Arakawa; Nobuo Kurokawa; Yasuo Tano
Journal:  Jpn J Ophthalmol       Date:  2006 Nov-Dec       Impact factor: 2.447

3.  High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection.

Authors:  O Weijtens; E J Feron; R C Schoemaker; A F Cohen; E G Lentjes; F P Romijn; J C van Meurs
Journal:  Am J Ophthalmol       Date:  1999-08       Impact factor: 5.258

4.  A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis.

Authors:  Cheryl A Arcinue; Olga M Cerón; C Stephen Foster
Journal:  J Ocul Pharmacol Ther       Date:  2013-01-08       Impact factor: 2.671

5.  Penetration of synthetic corticosteroids into human aqueous humour.

Authors:  C N McGhee; D G Watson; J M Midgley; M J Noble; G N Dutton; A I Fern
Journal:  Eye (Lond)       Date:  1990       Impact factor: 3.775

Review 6.  Pharmacokinetics of triamcinolone acetonide for the treatment of macular edema.

Authors:  Taygan Yilmaz; Miguel Cordero-Coma; Thomas J Federici
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-07-27       Impact factor: 4.481

7.  Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device.

Authors:  G J Jaffe; C H Yang; H Guo; J P Denny; C Lima; P Ashton
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

Review 8.  Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema.

Authors:  Mark Sanford
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

9.  Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants.

Authors:  Peter A Campochiaro; Quan Dong Nguyen; Gulnar Hafiz; Steven Bloom; David M Brown; Miguel Busquets; Thomas Ciulla; Leonard Feiner; Nelson Sabates; Kathleen Billman; Barry Kapik; Ken Green; Frances E Kane
Journal:  Ophthalmology       Date:  2012-12-04       Impact factor: 12.079

10.  Dexamethasone intravitreal implant for the treatment of noninfectious uveitis.

Authors:  Rebecca S Hunter; Ann-Marie Lobo
Journal:  Clin Ophthalmol       Date:  2011-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.